127 related articles for article (PubMed ID: 37981553)
21. Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification.
Akiba J; Nakashima O; Hattori S; Tanikawa K; Takenaka M; Nakayama M; Kondo R; Nomura Y; Koura K; Ueda K; Sanada S; Naito Y; Yamaguchi R; Yano H
Am J Surg Pathol; 2013 Apr; 37(4):496-505. PubMed ID: 23388123
[TBL] [Abstract][Full Text] [Related]
22. α-Fetoprotein-producing gastric carcinoma and combined hepatocellular and cholangiocarcinoma show similar morphology but different histogenesis with respect to SALL4 expression.
Ikeda H; Sato Y; Yoneda N; Harada K; Sasaki M; Kitamura S; Sudo Y; Ooi A; Nakanuma Y
Hum Pathol; 2012 Nov; 43(11):1955-63. PubMed ID: 22516245
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathological features and prognosis of combined hepatocellular carcinoma and cholangiocarcinoma after surgery.
Lee SD; Park SJ; Han SS; Kim SH; Kim YK; Lee SA; Ko YH; Hong EK
Hepatobiliary Pancreat Dis Int; 2014 Dec; 13(6):594-601. PubMed ID: 25475861
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathologic features of patients with intrahepatic cholangiocarcinoma who are seropositive for alpha-fetoprotein-L3 and those with combined hepatocellular and cholangiocarcinoma.
Okuda H; Shiratori K; Yamamoto M; Takasaki K; Nakano M
J Gastroenterol Hepatol; 2006 May; 21(5):869-73. PubMed ID: 16704538
[TBL] [Abstract][Full Text] [Related]
25. Long-Term Survival of Combined Hepatocellular-Cholangiocarcinoma: A Nationwide Study.
Chen PD; Chen LJ; Chang YJ; Chang YJ
Oncologist; 2021 Oct; 26(10):e1774-e1785. PubMed ID: 34213048
[TBL] [Abstract][Full Text] [Related]
26. Elevated neutrophil-to-lymphocyte ratio and predominance of intrahepatic cholangiocarcinoma prediction of poor hepatectomy outcomes in patients with combined hepatocellular-cholangiocarcinoma.
Chiu TJ; Chen YJ; Kuo FY; Chen YY
PLoS One; 2020; 15(12):e0240791. PubMed ID: 33306714
[TBL] [Abstract][Full Text] [Related]
27. Combined hepatocellular-cholangiocarcinoma: which preoperative clinical data and conventional MRI characteristics have value for the prediction of microvascular invasion and clinical significance?
Wang X; Wang W; Ma X; Lu X; Li S; Zeng M; Xu K; Yang C
Eur Radiol; 2020 Oct; 30(10):5337-5347. PubMed ID: 32385649
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Drug-Eluting Beads Transarterial Chemoembolization Combining Immune Checkpoint Inhibitors in Unresectable Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis.
Yang XG; Sun YY; Li DS; Xu GH; Huang XQ
Front Immunol; 2022; 13():940009. PubMed ID: 35874708
[TBL] [Abstract][Full Text] [Related]
29. Calcium channel blockers improve the prognosis of patients with intrahepatic cholangiocarcinoma after resection.
Kodama K; Kawaoka T; Kosaka M; Johira Y; Shirane Y; Miura R; Yano S; Murakami S; Amioka K; Naruto K; Ando Y; Kosaka Y; Uchikawa S; Fujino H; Nakahara T; Murakami E; Okamoto W; Yamauchi M; Miki D; Imamura M; Kuroda S; Kobayashi T; Ohdan H; Aikata H; Chayama K
J Gastroenterol; 2022 Sep; 57(9):676-683. PubMed ID: 35849192
[TBL] [Abstract][Full Text] [Related]
30. Prediction of Microvascular Invasion in Combined Hepatocellular-Cholangiocarcinoma Based on Pre-operative Clinical Data and Contrast-Enhanced Ultrasound Characteristics.
Chen Y; Lu Q; Zhu Y; Huang B; Dong Y; Wang W
Ultrasound Med Biol; 2022 Jul; 48(7):1190-1201. PubMed ID: 35397928
[TBL] [Abstract][Full Text] [Related]
31. Long-term prognosis of combined hepatocellular and cholangiocarcinoma after curative resection comparison with hepatocellular carcinoma and cholangiocarcinoma.
Lee JH; Chung GE; Yu SJ; Hwang SY; Kim JS; Kim HY; Yoon JH; Lee HS; Yi NJ; Suh KS; Lee KU; Jang JJ; Kim YJ
J Clin Gastroenterol; 2011 Jan; 45(1):69-75. PubMed ID: 20142755
[TBL] [Abstract][Full Text] [Related]
32. Tumor Microenvironment: Necroptosis Switches the Subtype of Liver Cancer While Necrosis Promotes Tumor Recurrence and Progression.
Özdemir BH
Exp Clin Transplant; 2023 Apr; 21(4):291-298. PubMed ID: 35297332
[TBL] [Abstract][Full Text] [Related]
33. Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma.
Kim KH; Lee SG; Park EH; Hwang S; Ahn CS; Moon DB; Ha TY; Song GW; Jung DH; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
Ann Surg Oncol; 2009 Mar; 16(3):623-9. PubMed ID: 19130133
[TBL] [Abstract][Full Text] [Related]
34. Clonorchis sinensis infection amplifies hepatocellular carcinoma stemness, predicting unfavorable prognosis.
Lin Q; Tang Z; Qin Y; Deng X; Wei C; Liu F; Pan X; Liu D; Zhan T; Fang M
PLoS Negl Trop Dis; 2024 Jan; 18(1):e0011906. PubMed ID: 38285640
[TBL] [Abstract][Full Text] [Related]
35. Comparing the clinicopathological characteristics of combined hepatocellular-cholangiocarcinoma with those of other primary liver cancers by use of the updated World Health Organization classification.
Yen CC; Yen CJ; Shan YS; Lin YJ; Liu IT; Huang HY; Yeh MM; Chan SH; Tsai HW
Histopathology; 2021 Oct; 79(4):556-572. PubMed ID: 33837585
[TBL] [Abstract][Full Text] [Related]
36. Treatment outcomes for unresectable intrahepatic cholangiocarcinoma: Nationwide, population-based, cohort study based on propensity score matching with the Mahalanobis metric.
Chang WW; Hsiao PK; Qin L; Chang CL; Chow JM; Wu SY
Radiother Oncol; 2018 Nov; 129(2):284-292. PubMed ID: 30279046
[TBL] [Abstract][Full Text] [Related]
37. Propensity-matched analysis of patients with intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma and hepatocellular carcinoma undergoing a liver transplant.
Brandão ABM; Rodriguez S; Fleck AM; Marroni CA; Wagner MB; Hörbe A; Fernandes MV; Cerski CT; Coral GP
World J Clin Oncol; 2022 Aug; 13(8):688-701. PubMed ID: 36160465
[TBL] [Abstract][Full Text] [Related]
38. Implications of ultrasound-based deep learning model for preoperatively differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Chen J; Zhang W; Bao J; Wang K; Zhao Q; Zhu Y; Chen Y
Abdom Radiol (NY); 2024 Jan; 49(1):93-102. PubMed ID: 37999743
[TBL] [Abstract][Full Text] [Related]
39. Intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma in patients undergoing liver transplantation: a Spanish matched cohort multicenter study.
Sapisochin G; de Lope CR; Gastaca M; de Urbina JO; López-Andujar R; Palacios F; Ramos E; Fabregat J; Castroagudín JF; Varo E; Pons JA; Parrilla P; González-Diéguez ML; Rodriguez M; Otero A; Vazquez MA; Zozaya G; Herrero JI; Antolin GS; Perez B; Ciria R; Rufian S; Fundora Y; Ferron JA; Guiberteau A; Blanco G; Varona MA; Barrera MA; Suarez MA; Santoyo J; Bruix J; Charco R
Ann Surg; 2014 May; 259(5):944-52. PubMed ID: 24441817
[TBL] [Abstract][Full Text] [Related]
40. Sarcopenia predicts an adverse prognosis in patients with combined hepatocellular carcinoma and cholangiocarcinoma after surgery.
Hou GM; Jiang C; Du JP; Yuan KF
Cancer Med; 2022 Jan; 11(2):317-331. PubMed ID: 34866356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
